ArticleGastrointestinal cancer : targets and therapy2018
Emerging treatment options for
Article in Gastrointestinal cancer : targets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Cellular and molecular events in colorectal cancer: biological mechanisms, cell death pathways, drug resistance and signalling network interactions.Discover oncology · 2024Review
- Small extracellular vesicles promote the formation of the pre-metastatic niche through multiple mechanisms in colorectal cancer.Cell cycle (Georgetown, Tex.) · 2024Review
- Review
- BRAFWorld journal of gastrointestinal oncology · 2021Article
- Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy.Journal of personalized medicine · 2021Review
- Molecular Oncology in Management of Colorectal Cancer.Indian journal of surgical oncology · 2021Article
- Personalized logical models to investigate cancer response to BRAF treatments in melanomas and colorectal cancers.PLoS computational biology · 2021Article
- Article
- BRAFJournal of experimental & clinical cancer research : CR · 2020Article
- Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focus.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- An amino-terminalCold Spring Harbor molecular case studies · 2020Article
- Stratification and prediction of drug synergy based on target functional similarity.NPJ systems biology and applications · 2020Article
- Increased Risk of Acute Myelogenous Leukemia After Early Onset but Not Late-Onset Colorectal Cancer.American journal of clinical oncology · 2020Article
- Personalised mapping of tumour development in synchronous colorectal cancer patients.NPJ genomic medicine · 2020Article
- GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAFFrontiers in oncology · 2020Article
- Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer.Frontiers in oncology · 2020Article
- Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.Nanotheranostics · 2020Article
- Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC).Diagnostics (Basel, Switzerland) · 2019Review
- Senescence-associated tissue microenvironment promotes colon cancer formation through the secretory factor GDF15.Aging cell · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The personalization of cancer care is rooted in the premise that there are subsets of patients with tumors harboring clinically relevant targets for patient-specific treatments. Colorectal cancer (CRC) is a disease that has historically been notable for its dearth of biomarkers that are predictive of response to targeted therapies. In recent years,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.